On December 4, 2020 Alligator Bioscience (Nasdaq Stockholm: ATORX) reported an approved IND (Investigational new Drug) for the CD40 targeting antibody mitazalimab (Press release, Alligator Bioscience, DEC 4, 2020, View Source [SID1234572159]). IND approval by the US Food and Drug Administration (FDA) is a prerequisite to start clinical trials in the USA. Recently, new benchmark data was published showing that mitazalimab has the potential to be best-in-class in the CD40 field. The comparison demonstrated the potent immune-activating properties and anti-tumor effects of mitazalimab.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"While the upcoming clinical Phase Ib/II study in pancreatic cancer, OPTIMIZE-1, will be starting in Europe, the IND opens up for later expansion in the US. This is essential for the future success of the product", said Per Norlén, CEO of Alligator Bioscience.", said Per Norlén, CEO of Alligator Bioscience. "Our key focus right now is to complete the submission of the CTA for start of OPTIMIZE-1 in the EU", he added.

The mitazalimab drug candidate has previously reported positive clinical data from a Phase I study performed by Janssen Biotech Inc., displaying a manageable safety profile as well as early signs of efficacy.

The information was submitted for publication, through the agency of the contact person set out above, at 9:00 a.m. CET on December 4, 2020.